Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling

BACKGROUND: Cisplatin resistance remains a major clinical obstacle to the successful treatment of non-small cell lung cancer (NSCLC). Scribble contributes to ROS-induced inflammation and cisplatin-elevated toxic reactive oxygen species (ROS) promotes cell death. However, it is unknown whether and ho...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:EBioMedicine
Autors principals: Wang, Na, Song, Lele, Xu, Yi, Zhang, Longfu, Wu, Yanjun, Guo, Jingyu, Ji, Weiwei, Li, Li, Zhao, Jingya, Zhang, Xin, Zhan, Lixing
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2019
Matèries:
Research paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6796531/
https://ncbi.nlm.nih.gov/pubmed/31495720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2019.08.057
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars